On Friday, Repligen Corp (NASDAQ: RGEN) was -12.43% drop from the session before settling in for the closing price of $142.43. A 52-week range for RGEN has been $113.50 – $211.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 31.42%. When this article was written, the company’s average yearly earnings per share was at -12.12%. With a float of $52.10 million, this company’s outstanding shares have now reached $55.77 million.
The extent of productivity of a business whose workforce counts for 1783 workers is very important to gauge. In terms of profitability, gross margin is 41.15%, operating margin of 1.23%, and the pretax margin is 1.69%.
Repligen Corp (RGEN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Repligen Corp stocks. The insider ownership of Repligen Corp is 6.98%, while institutional ownership is 99.88%. The most recent insider transaction that took place on Sep 10 ’24, was worth 3,225,927. In this transaction Director of this company sold 22,191 shares at a rate of $145.37, taking the stock ownership to the 139,840 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Officer proposed sale 22,191 for $144.72, making the entire transaction worth $3,211,481.
Repligen Corp (RGEN) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 0.33 earnings per share (EPS) during the time that was less than consensus figure (set at 0.34) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.00% during the next five years compared to 15.08% growth over the previous five years of trading.
Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators
You can see what Repligen Corp (RGEN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.93. Likewise, its price to free cash flow for the trailing twelve months is 51.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.37, a number that is poised to hit 0.42 in the next quarter and is forecasted to reach 1.77 in one year’s time.
Technical Analysis of Repligen Corp (RGEN)
The latest stats from [Repligen Corp, RGEN] show that its last 5-days average volume of 1.17 million was superior to 0.67 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 41.08%. Additionally, its Average True Range was 7.62.
During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 12.90%, which indicates a significant increase from 9.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.65% in the past 14 days, which was higher than the 55.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $141.09, while its 200-day Moving Average is $157.32. Now, the first resistance to watch is $136.76. This is followed by the second major resistance level at $148.79. The third major resistance level sits at $156.41. If the price goes on to break the first support level at $117.11, it is likely to go to the next support level at $109.49. Assuming the price breaks the second support level, the third support level stands at $97.46.
Repligen Corp (NASDAQ: RGEN) Key Stats
There are 56,007K outstanding shares of the company, which has a market capitalization of 6.12 billion. As of now, sales total 638,760 K while income totals 41,580 K. Its latest quarter income was 154,070 K while its last quarter net income were 3,320 K.
